Biolevate, a Paris, France-based software company accelerating healthcare innovations through artificial intelligence, raised EUR 6M in Seed funding.
The round was led by EQT Ventures, with participation from bpifrance and angel investors.
The company intends to use the funds to further enhance its product and hire talent.
Led by CEO Joël Belafa, Biolevate is an AI-driven company focused on accelerating market access for therapeutic innovations by addressing the regulatory and operational challenges that often delay drug availability. With a platform designed to streamline the entire market access process, it offers fully transparent, teachable, and collaborative solutions tailored to the pharmaceutical, cosmetic, and medical device industries. Supported by a team of AI and healthcare experts, it leverages predictive analytics, automated data extraction, and project management tools to reduce time-to-market while ensuring compliance with regulatory standards.
Its proprietary AI driven-platform ELISE is designed to support medical writers by optimizing the creation and management of research and compliance documents, leveraging Natural Language Processing (NLP) and Computer Vision and Graph Neural Networks (GNN).
ELISE offers real-time collaborative writing that meets rigorous regulatory standards, with instant suggestions and edits to text, compliance-, and literature review assistance, and effectively works as an assistant to anyone writing medical documents.
FinSMEs
26/11/2024